UniProt O60674
Tyrosine-protein kinase JAK2 (O60674)
Tyrosine-protein kinase JAK2 (UniProt O60674), EC 2.7.10.2: 209 experimental structures on GenesisL1, 74 ligands bound, 91 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- O60674
- Protein
- Tyrosine-protein kinase JAK2
- EC
- 2.7.10.2
- Experimental structures
- 209
- Predicted models
- 0
- Ligands
- 74
- Pockets
- 91 · 19 records with a druggable one
Structures
209 records of O60674 in the MolNFT archive: 209 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2B7A | The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase… | x-ray diffraction | A, B | — | — |
| 2B7A | The structural basis of janus kinase 2 inhibition by a potent and specific pan-janus kinase… | x-ray diffraction | A, B | — | — |
| 2W1I | Structure determination of Aurora Kinase in complex with inhibitor | x-ray diffraction | A, B | — | — |
| 2W1I | Structure determination of aurora kinase in complex with inhibitor | x-ray diffraction | A, B | — | — |
| 2XA4 | Inhibitors of Jak2 Kinase domain | x-ray diffraction | A, B | — | — |
| 2XA4 | Inhibitors of JAK2 kinase domain | x-ray diffraction | A, B | — | — |
| 3E62 | Fragment based discovery of JAK-2 inhibitors | x-ray diffraction | A | — | — |
| 3E62 | Fragment based discovery of JAK-2 inhibitors | x-ray diffraction | A | — | — |
| 3E63 | Fragment based discovery of JAK-2 inhibitors | x-ray diffraction | A | — | — |
| 3E63 | Fragment based discovery of JAK-2 inhibitors | x-ray diffraction | A | — | — |
| 3E64 | Fragment based discovery of JAK-2 inhibitors | x-ray diffraction | A | — | — |
| 3E64 | Fragment based discovery of JAK-2 inhibitors | x-ray diffraction | A | — | — |
| 3FUP | Crystal structures of JAK1 and JAK2 inhibitor complexes | x-ray diffraction | A, B | — | — |
| 3FUP | Crystal structures of JAK1 and JAK2 inhibitor complexes | x-ray diffraction | A, B | — | — |
| 3IO7 | 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2 | x-ray diffraction | A | — | — |
| 3IO7 | 2-AMINOPYRAZOLO[1,5-A]PYRIMIDINES as potent and selective inhibitors of JAK2 | x-ray diffraction | A | — | — |
| 3IOK | 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2 | x-ray diffraction | A | — | — |
| 3IOK | 2-AMINOPYRAZOLO[1,5-A]PYRIMIDINES as potent and selective inhibitors of JAK2 | x-ray diffraction | A | — | — |
| 3JY9 | Janus Kinase 2 Inhibitors | x-ray diffraction | A | — | — |
| 3JY9 | Janus kinase 2 inhibitors | x-ray diffraction | A | — | — |
| 3KCK | A Novel Chemotype of Kinase Inhibitors | x-ray diffraction | A | — | — |
| 3KCK | A novel chemotype of kinase inhibitors | x-ray diffraction | A | — | — |
| 3KRR | Crystal Structure of JAK2 complexed with a potent quinoxaline ATP site inhibitor | x-ray diffraction | A | — | — |
| 3KRR | Crystal structure of JAK2 complexed with a potent quinoxaline ATP site inhibitor | x-ray diffraction | A | — | — |
| 3LPB | Crystal structure of Jak2 complexed with a potent 2,8-diaryl-quinoxaline inhibitor | x-ray diffraction | A, B | — | — |
| 3LPB | Crystal structure of JAK2 complexed with a potent 2,8-diaryl- quinoxaline inhibitor | x-ray diffraction | A, B | — | — |
| 3Q32 | Structure of Janus kinase 2 with a pyrrolotriazine inhibitor | x-ray diffraction | A, B | — | — |
| 3Q32 | Structure of janus kinase 2 with a pyrrolotriazine inhibitor | x-ray diffraction | A, B | — | — |
| 3RVG | Crystals structure of Jak2 with a 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitor | x-ray diffraction | A | — | — |
| 3RVG | Crystals structure of JAK2 with a 1-amino-5H-PYRIDO[4,3-B]INDOL-4- carboxamide inhibitor | x-ray diffraction | A | — | — |
| 3TJC | Co-crystal structure of jak2 with thienopyridine 8 | x-ray diffraction | A, B | — | — |
| 3TJC | Co-crystal structure of JAK2 with thienopyridine 8 | x-ray diffraction | A, B | — | — |
| 3TJD | co-crystal structure of Jak2 with thienopyridine 19 | x-ray diffraction | A, B | — | — |
| 3TJD | Co-crystal structure of JAK2 with thienopyridine 19 | x-ray diffraction | A, B | — | — |
| 3UGC | Structural basis of Jak2 inhibition by the type II inhibtor NVP-BBT594 | x-ray diffraction | A | — | — |
| 3UGC | Structural basis of JAK2 inhibition by the type II inhibtor nvp-BBT594 | x-ray diffraction | A | — | — |
| 3ZMM | Inhibitors of Jak2 Kinase domain | x-ray diffraction | A, B | — | — |
| 3ZMM | Inhibitors of JAK2 kinase domain | x-ray diffraction | A, B | — | — |
| 4AQC | Triazolopyridine-based Inhibitor of Janus Kinase 2 | x-ray diffraction | A, B | — | — |
| 4AQC | Triazolopyridine-based inhibitor of janus kinase 2 | x-ray diffraction | A, B | — | — |
| 4BBE | Aminoalkylpyrimidine Inhibitor Complexes with JAK2 | x-ray diffraction | A, B, C, D | — | — |
| 4BBE | Aminoalkylpyrimidine inhibitor complexes with JAK2 | x-ray diffraction | A, B, C, D | — | — |
| 4BBF | Aminoalkylpyrimidine Inhibitor Complexes with JAK2 | x-ray diffraction | A, B, C, D | — | — |
| 4BBF | Aminoalkylpyrimidine inhibitor complexes with JAK2 | x-ray diffraction | A, B, C, D | — | — |
| 4C61 | Inhibitors of Jak2 Kinase domain | x-ray diffraction | A, B | — | — |
| 4C61 | Inhibitors of JAK2 kinase domain | x-ray diffraction | A, B | — | — |
| 4C62 | Inhibitors of Jak2 Kinase domain | x-ray diffraction | A, B | — | — |
| 4C62 | Inhibitors of JAK2 kinase domain | x-ray diffraction | A, B | — | — |
| 4D0W | Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | x-ray diffraction | A | — | — |
| 4D0W | Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | x-ray diffraction | A | — | — |
| 4D0X | Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | x-ray diffraction | A | — | — |
| 4D0X | Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | x-ray diffraction | A | — | — |
| 4D1S | Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | x-ray diffraction | A | — | — |
| 4D1S | Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | x-ray diffraction | A | — | — |
| 4E4M | JAK2 kinase (JH1 domain) in complex with compound 30 | x-ray diffraction | A, B, D, E | — | — |
| 4E4M | JAK2 kinase (JH1 domain) in complex with compound 30 | x-ray diffraction | A, B, D, E | — | — |
| 4E6D | JAK2 kinase (JH1 domain) triple mutant in complex with compound 7 | x-ray diffraction | A, B | — | — |
| 4E6D | JAK2 kinase (JH1 domain) triple mutant in complex with compound 7 | x-ray diffraction | A, B | — | — |
| 4E6Q | JAK2 kinase (JH1 domain) triple mutant in complex with compound 12 | x-ray diffraction | A, B | — | — |
| 4E6Q | JAK2 kinase (JH1 domain) triple mutant in complex with compound 12 | x-ray diffraction | A, B | — | — |
149 records more on the page itself.
Ligands
- SKE · 4-({5-amino-1-[(2,6-difluorophenyl)carbonyl]-1H-1,2,4-triazol-3-yl}amino)benzenesulfonamide · in 5 records
- RXT · (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile · in 4 records
- 35R · 1-cyclopropyl-3-{3-[5-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl}urea · in 3 records
- 3JW · Baricitinib · in 3 records
- 2TA · N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl) ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide · in 2 records
- 36H · 2-((1-(2-fluoro-4-((4-(1-isopropyl-1H-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl) (methyl)amino)ethan-1-ol · in 2 records
- 4SP · O6-cyclohexylmethoxy-2-(4'-sulphamoylanilino) purine · in 2 records
- 584 · (7R)-2-[(3,5-difluoro-4-hydroxyphenyl)amino]-5,7-dimethyl-8-(3-methylbutyl)-7,8-dihydropteridin-6(5H)-one · in 2 records
- 6DP · ~{N}-(1~{H}-indazol-4-yl)methanesulfonamide · in 2 records
- AQG · 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide · in 2 records
- D7D · N-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl) amino]cyclobutyl}propane-1-sulfonamide · in 2 records
- DQX · 8-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-2-(1-piperidin-4-yl-1H-pyrazol-4-yl)quinoxaline · in 2 records
- E4V · 4-(5-aminopyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridin-6-amine · in 2 records
- M3A · 5-amino-3-[(4-cyanophenyl)amino]-N-phenyl-1H-1,2,4-triazole-1-carboxamide · in 2 records
- M4P · [4-({5-amino-3-[(4-cyanophenyl)amino]-1H-1,2,4-triazole-1-carbonyl}amino)phenoxy]acetic acid · in 2 records
- R5S · 3-[4-(2-{[4-(piperidin-4-yl)phenyl]amino}-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile · in 2 records
- R61 · 2-{5-[(2-{[3,5-difluoro-4-(1-methylpiperidin-4-yl) phenyl]amino}-5-methylpyrimidin-4-yl)amino]-2-fluorophenyl}-1lambda~6~,2-thiazolidine-1,1-dione · in 2 records
- R6M · N-{2-fluoro-5-[(2-{[3-fluoro-4-(1-methylpiperidin-4-yl)phenyl]amino}-5-methylpyrimidin-4-yl)amino]phenyl}-2-methylpropane-2-sulfonamide · in 2 records
- R6V · (3R)-3-cyclopentyl-3-[4-(2-{[4-(piperidin-4-yl) phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile · in 2 records
- SO4 · Sulfate ion · in 2 records
- U8J · N-methyl-4-{[4-(1-propyl-1H-pyrazol-4-yl)-7H-pyrrolo[2, 3-d]pyrimidin-2-yl]amino}benzamide · in 2 records
- UWP · [3-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl}-1-(2,2,2-trifluoroethyl)azetidin-3-yl]acetonitrile · in 2 records
- Y5G · {1-(ethylsulfonyl)-3-[4-(2-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile · in 2 records
- 046 · 5-{[6-(acetylamino)pyrimidin-4-yl]oxy}-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl) phenyl}-2,3-dihydro-1H-indole-1-carboxamide · in 1 record
- 1M3 · N-tert-butyl-3-[(5-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide · in 1 record
- 2HB · N-(5-{4-[(1,1-dioxidothiomorpholin-4-yl) methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl) cyclopropanecarboxamide · in 1 record
- 3YT · 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-{[3-(2H-1,2,3-triazol-2-yl)phenyl]amino}pyrimidine-5-carboxamide · in 1 record
- 4LY · [3-(4-{2-[3,5-difluoro-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)-1-(ethanesulfonyl) azetidin-3-yl]acetonitrile · in 1 record
- 50O · N,N-dicyclopropyl-6-[(2S)-2,3-dihydroxypropyl]-1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide · in 1 record
- 50Y · N,N-dicyclopropyl-6-ethyl-4-[(3-methoxypropyl)amino]-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.